19. - 20.11.2015 - FutureTox III: Bridges for Translation


Transforming 21st Century Science into Risk Assessment and Regulatory Decision-Making

The 21st Century vision and strategy for assessing toxicity (TT21C science or Tox21 hereafter) was developed with the intent to increase throughput, decrease cost, and optimize chemical data collection for increased utility and relevance to inform chemical safety decision-making. Central to this strategy is the ability to predict human health risks from emerging ‘‘big data” and novel in vitro data collections using in silico models for exposure and hazard assessment. Automated high-throughput screening (HTS) and high-content screening (HCS) of large chemical inventories, together with newer complex culture models utilizing human cells, microtissue systems, and integrative models, are now providing vast amounts of data that can be used to inform regulatory toxicity testing. These methods, together with novel approaches to model exposure and kinetics, creates an opportunity for a paradigm shift toward diversified and high-throughput risk assessment (HTRA) approaches for regulatory decision-making. Overall, the approach results in more rapid, more relevant, and more nimble discovery-screening and prioritization efforts with less reliance on animal testing. The time is right to discuss and debate how TT21C science, approaches, and technologies will be applied in risk assessment and regulatory decision-making.

19. - 20. November, 2015

Hilton Crystal City at Washington National Airport, Arlington, Virginia

Characterization of 3D HepaRG microtissues for long-term toxicity studies

Pro-drug activation and detoxification in a dynamic
microfluidic system

OMICS analysis of human liver microtissues stability grown over 4 weeks


More information about the FutureTox III


Company video